• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Relation cMet and Topoisomerase I in lung cancer

Research Project

Project/Area Number 23501306
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Clinical oncology
Research InstitutionKanazawa University

Principal Investigator

KASAHARA Kazuo  金沢大学, 医学系, 准教授 (30272967)

Project Period (FY) 2011 – 2013
Project Status Completed (Fiscal Year 2013)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywords肺癌 / cMet / Toposioemrase I / 分子標的治療 / Topoisomerase I / cMet
Research Abstract

Personalized therapy progresses in the treatment of the lung cancer. cMet is important as a drug-resistant factor for the EGFR tyrosine kinase inhibitor. DNA topoisomerase I (TopoI) is necessary for replication of DNA and is a target enzyme of irinotecan. We focused on the relation between these two protein . cMet up-regulate expression of TopoI in lung cancer cell lines, and we showed that it prescribed sensitivity of irinotecan, a TopoI inhibitor. Furthermore, We showed that TopoI correlated to Met protein in the tumor sample of the lung cancer patients and that cMet protein was the prognostic factor.
As for this study, it is significant for progress of the personalized therapy for lung cancer treatment.

Report

(4 results)
  • 2013 Annual Research Report   Final Research Report ( PDF )
  • 2012 Research-status Report
  • 2011 Research-status Report
  • Research Products

    (9 results)

All 2013 2012

All Journal Article (5 results) (of which Peer Reviewed: 5 results) Presentation (4 results)

  • [Journal Article] Antitumor effects of inductive hyperthermia using magnetic ferucarbotran nanoparticles on human lung cancer xenografts in nude mice.2013

    • Author(s)
      Araya T, Kasahara K, Nishikawa S, Kimura H, Sone T, Nagae H, Ikehata Y, Nagano I, Fujimura M.
    • Journal Title

      Onco Targets and Therapy

      Volume: 6 Pages: 237-242

    • DOI

      10.2147/ott.s42815

    • NAID

      120005821070

    • Related Report
      2013 Final Research Report 2012 Research-status Report
    • Peer Reviewed
  • [Journal Article] Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma2013

    • Author(s)
      Watanabe S, Sone T, Matsui T, Yamamura K, Tani M, Okazaki A, Kurokawa K, Tambo Y, Takato H, Ohkura N, Waseda Y, Katayama N, Kasahara K
    • Journal Title

      Lung Cancer

      Volume: 82, 2 Issue: 2 Pages: 370-372

    • DOI

      10.1016/j.lungcan.2013.06.003

    • Related Report
      2013 Final Research Report
    • Peer Reviewed
  • [Journal Article] Detection of EGFR T790M Mutation in Pericardial Effusion from a Non-Small Cell Lung Cancer Patient with Erlotinib Therapy.2013

    • Author(s)
      Sakai A, Kasahara K, Sone T.
    • Journal Title

      Case Report in Oncology

      Volume: 6 Issue: 1 Pages: 15-20

    • DOI

      10.1159/000345947

    • Related Report
      2013 Final Research Report 2012 Research-status Report
    • Peer Reviewed
  • [Journal Article] MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.2012

    • Author(s)
      Sakai A, Kasahara K, Ohmori T, Kimura H, Sone T, Fujimura M, Nakao S.
    • Journal Title

      Journal of Thoracic Oncology

      Volume: 7 Issue: 9 Pages: 1337-1344

    • DOI

      10.1097/jto.0b013e31825cca4c

    • Related Report
      2013 Final Research Report 2012 Research-status Report
    • Peer Reviewed
  • [Journal Article] MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity2012

    • Author(s)
      Asao Sakai、Kazuo Kasahara、Takashi Sone
    • Journal Title

      Journal of Thoracic Oncology

      Volume: in press

    • Related Report
      2011 Research-status Report
    • Peer Reviewed
  • [Presentation] Prognostic impact of cMet/phosphor-Met and Topoisomerase I in small cell lung cancer2012

    • Author(s)
      Hideko Ikeda、Kazuo Kasahara, Koji Kurokawa, et al
    • Organizer
      5^<th> Asia Pacific Lung Cancer Conference
    • Place of Presentation
      ヒルトン福岡シーホーク(福岡県)
    • Related Report
      2013 Final Research Report
  • [Presentation] Prognostic impact of cMet/phosphor-Met and Topoisomerase I in small cell lung cancer2012

    • Author(s)
      池田栄子、笠原寿郎、黒川浩二、ほか
    • Organizer
      第50回日本癌治療学会学術総会
    • Place of Presentation
      パシフィコ横浜 (神奈川県)
    • Related Report
      2013 Final Research Report
  • [Presentation] Prognostic impact of c-Met/phospho-Met and Topoisomerase I in small cell lung cancer2012

    • Author(s)
      池田栄子 笠原寿郎 黒川浩二 酒井麻夫 西川晋吾 丹保祐一 新屋智之 曽根崇 福岡順也 藤村政樹 中尾眞二
    • Organizer
      日本癌治療学会
    • Place of Presentation
      パシフィコ横浜(神奈川県)
    • Related Report
      2012 Research-status Report
  • [Presentation] Prognostic impact of c-Met/phospho-Met and Topoisomerase I in small cell lung cancer2012

    • Author(s)
      Hideko Ikeda, Kazuo Kasahara, Koji Kurokawa, Asao Sakai, Shingo Nishikawa, Yuichi Tanbo, Tomoyuki Araya, Takashi Sone, Jyunya Fukuoka
    • Organizer
      5th Asia Pacific Lung Cancer Conference
    • Place of Presentation
      ヒルトン福岡シーホークホテル(福岡県)
    • Related Report
      2012 Research-status Report

URL: 

Published: 2011-08-05   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi